Status:
NOT_YET_RECRUITING
Effects of a Multicomponent Exercise Program Incorporating Waltz Dance on Postmenopausal Women With Dyslipidemia: A Randomized Controlled Trial
Lead Sponsor:
Gdansk University of Physical Education and Sport
Conditions:
Dyslipaemia
Eligibility:
FEMALE
45-65 years
Phase:
NA
Brief Summary
Brief Summary: The goal of this clinical trial is to evaluate whether a 12-week multicomponent exercise program-combining Waltz dance, resistance training, and agility training-can improve physiologi...
Eligibility Criteria
Inclusion
- Age: Postmenopausal women aged ≤65 years at the time of enrollment.
- Menopausal Status: Natural menopause defined as spontaneous cessation of menstruation for ≥12 consecutive months, excluding menopause due to pathological or surgical causes (e.g., oophorectomy, thyroid disorders).
- Dyslipidemia: Presence of one or more of the following lipid abnormalities:
- High-density lipoprotein cholesterol (HDL-C) \< 1.04 mmol/L Triglycerides (TG) ≥ 1.7 mmol/L Low-density lipoprotein cholesterol (LDL-C) ≥ 3.0 mmol/L Total cholesterol (TC) ≥ 5.18 mmol/L
- Obesity or Sarcopenic Tendency: Body fat percentage \> 30%, as measured by validated body composition analyzer.
- Physical Capability: No musculoskeletal injuries, physical disabilities, or contraindications to exercise. Participants must be cleared using the Physical Activity Readiness Questionnaire (PAR-Q).
- Sedentary Lifestyle: Engaging in structured physical activity ≤3 times per week, with each session lasting ≤20 minutes, in the last 6 months.
- No Recent Weight Control Interventions: No use of weight-loss supplements or engagement in intentional weight loss through diet or exercise in the past year.
- Voluntary Participation: Willingness to participate in the study and provide written informed consent (Informed Consent Form, ICF).
Exclusion
- Metabolic or Endocrine Disorders: History of insulin-dependent diabetes mellitus, untreated or unstable thyroid dysfunction, Cushing's syndrome, or other serious endocrine diseases.
- Cardiovascular Disease: Uncontrolled hypertension, arrhythmias, congestive heart failure, or a history of myocardial infarction or stroke within the past 6 months.
- Severe Respiratory Conditions: Chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, or any condition significantly limiting exercise tolerance.
- Neurological Disorders: Parkinson's disease, post-stroke sequelae, moderate to severe cognitive impairment, or Alzheimer's disease.
- Inflammatory or Autoimmune Diseases: Active rheumatoid arthritis, Crohn's disease, or other chronic inflammatory conditions.
- Cancer: Diagnosis of any malignancy within the past 5 years.
- Musculoskeletal Limitations: Diagnosed severe osteoporosis or a history of falls or fractures within the past 6 months.
- Extremes of Body Mass Index (BMI): BMI ≥35 kg/m² or \<18.5 kg/m².
- Substance Use: Current drug abuse, heavy alcohol consumption (defined as \>70 g alcohol/week), or heavy smoking (≥10 cigarettes/day) that cannot be reduced during the study period.
- Dietary Extremes: Strict vegetarian, ketogenic, or other extreme dietary patterns that may affect metabolic outcomes.
- Medications:
- Current hormone replacement therapy (e.g., estrogen, testosterone). Use of antidepressants in the past 6 months. Regular use of medications affecting lipid metabolism, bone health, or cardiovascular function (e.g., aspirin, statins, antihypertensive or antidiabetic drugs).
- Recent Structured Exercise: Participation in structured dance, resistance, or agility training within the past 12 months.
Key Trial Info
Start Date :
May 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 20 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06985550
Start Date
May 20 2025
End Date
September 20 2025
Last Update
May 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
School of Physical Education, Sichuan Normal University
Chengdu, Sichuan, China, 610101